Evoke Pharma Stock Performance
| EVOK Stock | USD 4.35 0.02 0.46% |
Evoke Pharma has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.26, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Evoke Pharma will likely underperform. Evoke Pharma right now shows a risk of 6.35%. Please confirm Evoke Pharma semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if Evoke Pharma will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Evoke Pharma are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite quite inconsistent basic indicators, Evoke Pharma may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return (0.90) | Five Day Return (5.87) | Year To Date Return (65.12) | Ten Year Return (99.51) | All Time Return (99.75) |
Last Split Factor 1:12 | Last Split Date 2024-08-01 |
1 | Disposition of 375 shares by Donofrio Matthew J of Evoke Pharma at 0.62 subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Marilyn Carlson of 75000 shares of Evoke Pharma at 0.62 subject to Rule 16b-3 | 09/12/2024 |
3 | Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments | 09/19/2024 |
4 | Acquisition by Garner Cam L of 67500 shares of Evoke Pharma at 0.66 subject to Rule 16b-3 | 09/26/2024 |
5 | Acquisition by Donofrio Matthew J of 150000 shares of Evoke Pharma at 2.94 subject to Rule 16b-3 | 10/07/2024 |
6 | Disposition of 40357 shares by Donofrio Matthew J of Evoke Pharma at 2.91 subject to Rule 16b-3 | 10/11/2024 |
7 | Insider Trading | 10/18/2024 |
8 | Evoke Pharma Gains Momentum with GIMOTI Study Success | 10/28/2024 |
9 | What Financial Challenges Does Evoke Pharma Face | 10/29/2024 |
10 | Evoke Pharma earnings missed by 0.95, revenue fell short of estimates | 11/08/2024 |
11 | Evoke Pharma Now Covered by StockNews.com | 11/14/2024 |
| Begin Period Cash Flow | 9.8 M |
Evoke |
Evoke Pharma Relative Risk vs. Return Landscape
If you would invest 440.00 in Evoke Pharma on August 28, 2024 and sell it today you would lose (5.00) from holding Evoke Pharma or give up 1.14% of portfolio value over 90 days. Evoke Pharma is currently generating 0.1654% in daily expected returns and assumes 6.3484% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Evoke, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evoke Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evoke Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evoke Pharma, and traders can use it to determine the average amount a Evoke Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.026
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EVOK | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.35 actual daily | 56 56% of assets are less volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Evoke Pharma is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evoke Pharma by adding it to a well-diversified portfolio.
Evoke Pharma Fundamentals Growth
Evoke Stock prices reflect investors' perceptions of the future prospects and financial health of Evoke Pharma, and Evoke Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evoke Stock performance.
| Return On Equity | -3.5 | ||||
| Return On Asset | -0.33 | ||||
| Profit Margin | (0.71) % | ||||
| Operating Margin | (0.48) % | ||||
| Current Valuation | 125.11 K | ||||
| Shares Outstanding | 1.49 M | ||||
| Price To Earning | (3.21) X | ||||
| Price To Book | 1.47 X | ||||
| Price To Sales | 0.75 X | ||||
| Revenue | 5.18 M | ||||
| Gross Profit | 2.14 M | ||||
| EBITDA | (7.29 M) | ||||
| Net Income | (7.79 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 4.02 X | ||||
| Total Debt | 5 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 10.65 X | ||||
| Book Value Per Share | 4.90 X | ||||
| Cash Flow From Operations | (4.98 M) | ||||
| Earnings Per Share | (10.13) X | ||||
| Market Capitalization | 6.46 M | ||||
| Total Asset | 7.07 M | ||||
| Retained Earnings | (123.44 M) | ||||
| Working Capital | 3.79 M | ||||
| Current Asset | 9.52 M | ||||
| Current Liabilities | 1.83 M | ||||
About Evoke Pharma Performance
By examining Evoke Pharma's fundamental ratios, stakeholders can obtain critical insights into Evoke Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Evoke Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 871.17 | 648.49 | |
| Return On Tangible Assets | (1.10) | (1.16) | |
| Return On Capital Employed | (1.84) | (1.93) | |
| Return On Assets | (1.10) | (1.16) | |
| Return On Equity | 3.02 | 3.17 |
Things to note about Evoke Pharma performance evaluation
Checking the ongoing alerts about Evoke Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evoke Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evoke Pharma had very high historical volatility over the last 90 days | |
| Evoke Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.18 M. Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 2.14 M. | |
| Evoke Pharma currently holds about 13.45 M in cash with (4.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.02. | |
| Latest headline from MacroaxisInsider: Insider Trading |
- Analyzing Evoke Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evoke Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Evoke Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evoke Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evoke Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evoke Pharma's stock. These opinions can provide insight into Evoke Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.13) | Revenue Per Share 7.792 | Quarterly Revenue Growth 0.698 | Return On Assets (0.34) | Return On Equity (3.50) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.